With so much information available, it can be difficult to navigate your options
It's important to note that Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management, while Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management, though sometimes used off-label for weight loss
- Klarity Health, accessed April 23, 2025, Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End - Pharmacy Times, accessed April 23, 2025, Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance - HealthDay, accessed April 23, 2025, Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, accessed April 23, 2025, Continuing Semaglutide Leads to Further Weight Loss - NEJM Journal Watch, accessed April 23, 2025, Zepbound vs Wegovy for Weight Loss - Connecticut Facial Plastic Surgery, accessed April 23, 2025, Fills for Weight-Loss Medications Like Wegovy and Mounjaro Rise Despite High Out-of-Pocket Costs - GoodRx, accessed April 23, 2025,
It also acts as a cryoprotectant during the freeze-drying process that many compounded formulations undergo, protecting the peptide structure from freezing-related damage
Does the Keto Diet Increase the Risk of Diabetes
10 Industry-Wide Trend Highlights Significant Shareholder Returns: The industry-wide average ratio of 0.81 indicates that, across leading pharmaceutical companies, R&D spending modestly exceeds shareholder returns on average
